About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Find trials: by AGENT | by TYPE of LYMPHOMA AND treatment status | of INTEREST

   Search Site | Ask Question | Sign Guest book |  How to Help!

Patients Against Lymphoma

 

Treatments or Clinical Trials Clinical Trials of Interest

Clinical Circumstance:  First Primary Therapy for Previously Untreated

Last update: 11/21/2011 

First Line Low Toxic  | First Primary Therapy |
Relapsed / refractory | Addressing other unmet needs

First Primary Therapy for Previously Untreated Lymphomas

Subtypes: 
 
DLBCL / aggressive | Follicular / Low grade | Mantle Cell | T-cell | CLL/SLL | CNS

  Search First line Therapies for Lymphoma


What's New

bullet
R-CHOP + Azacytidine  
 
See for Azacytidine 

Condition: Previously untreated Diffuse Large B-cell Lymphoma 
 

Untreated Diffuse Large B-Cell Lymphoma /
aggressive b-cell lymphoma

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert. 

bullet
R-CHOP + Azacytidine  
 
See for Azacytidine
 

Condition: Previously untreated Diffuse Large B-cell Lymphoma 
bullet
R-CHOP Versus. Dose-Adjusted EPOCH-R With Molecular Profiling 

Condition: Previously untreated Diffuse Large B-cell Lymphoma 
bullet
Lenalidomide (Revlimid), plus CHOP-R  
 

See for Lenalidomide


Condition: Previously untreated Diffuse Large B-cell Lymphoma 
 
bullet
Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy

Condition: Previously untreated Diffuse Large B-cell Lymphoma
 
bullet
Rituxan + CHOP versus Dose-Adjusted EPOCH-Rituxan with molecular Profiling
  
Condition: Previously untreated Diffuse Large B-cell Lymphoma
bullet

Bexxar with CHOP-Rituxan (SWOG-0433)

Condition: Patients ≥ Age 60 With Advanced Stage Diffuse Large B-Cell NHL
bullet
Vorinostat (Zolinza* ), Rituxan, and Combination Chemotherapy  
 
See for Zolinza 


Condition: Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
bullet
RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy  
 
See for Everolimus (RAD001)

Condition: high risk Diffuse Large B-Cell Lymphoma in complete response


CNS Lymphoma

bullet
Temozolomide-based Clinical trials: http://bit.ly/cTcM0O

Report http://bit.ly/biziKd


Untreated Follicular Lymphoma or Low Grade Lymphoma

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert.  

Search: first line for indolent lymphomas
 

Early stage:

bullet
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma 

New combinations:

bullet
Combination Veltuzumab (Anti-CD20) AND 
Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy

Condition:  Patients With Follicular Lymphoma
bullet
Rituxan, Cyclophosphamide, Velcade, and Prednisone  

Condition: Previously untreated stage III or IV follicular and Marginal Zone lymphomas
bullet
Bendamustine, Mitoxantrone, and Rituximab (BMR) 

Condition: Previously untreated high risk follicular lymphoma 
(as defined by a FLIPI score >/= 3.)
bullet
Lenalidomide (Revlimid), Rituxan, and Combination Chemotherapy

Condition: Previously untreated follicular lymphoma, stage II-IV 

Radioimmunotherapy-based:

bullet
Low-Dose MTX and Bexar for Untreated Follicular Lymphoma    ‎

"In addition to evaluating the occurrence of HAMA, this research study will also look at the short and long-term effectiveness of this combination in the treatment of lymphoma, as well as its safety."
bullet
Dose-Response in Radioimmunotherapy of Lymphoma  

Condition: Eligible, by standard of care criteria, for Bexxar or Zevalin treatment
 
bullet
Bexxar or Zevalin as  First Therapy of Lymphoma 

Condition: Previously untreated b-cell lymphoma 
bullet
Bexxar, Rituxan, and Combination Chemotherapy 

Condition: Previously untreated stage III or IV follicular lymphoma 
bullet
Zevalin Following R-CVP versus Observation

Condition: Previously untreated high risk follicular lymphoma as defined by a follicular lymphoma international prognostic index (FLIPI) of 3, 4, or 5 assessed within 3 months prior to randomization." 


Untreated Mantle Cell lymphoma

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert. 

bullet
Bexxar followed by six cycles of CHOP
 
Condition: Previously untreated Mantle Cell Lymphoma
bullet
Vaccine with Interleukin-2 After Combination Chemotherapy
  
Condition: Previously treated, or untreated, Mantle Cell Lymphoma


Untreated T-cell lymphoma (under construction)

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert. 

bullet
Brentuximab Vedotin Given Sequentially and Combined With CHOP http://1.usa.gov/fgBeT3

Condition: Anaplastic Large Cell Lymphoma

"Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody linked to a potent, synthetic drug payload, monomethyl auristatin E (MMAE)"

Clinical report: http://www.ncbi.nlm.nih.gov/pubmed/21047225
bullet
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP 

Conditions: Peripheral T Cell Lymphoma, Unspecified;   Angioimmunoblastic Lymphadenopathy;   AIL Type Lymphoma;   Anaplastic Large Cell Lymphoma, ALK Negative;   Extranodal NK/T-Cell Lymphoma
bullet
Alemtuzumab and CHOP in T-cell Lymphoma 

Conditions: Lymphoma, T-Cell, Peripheral
bullet
CHOP and ONTAK
 
Conditions: Treatment nave, except for prior radiation or a single cycle of CHOP
T-Cell lymphoma, REAL classification 

 


Untreated Hodgkins lymphoma (under construction)

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert.   

bullet
KGEL Vaccine After Initial Chemotherapy

Condition: Previously untreated Hodgkin's Disease

 


Untreated CLL/SLL (under construction)

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert. 

bullet
Lenalidomide as Initial Treatment,  Age 65 and Older
bullet
Fludarabine and Rituxan Followed  by Bexxar 
 
Conditions Previously untreated:  Chronic Lymphocytic Leukemia (CLL) ; 
Small Lymphocytic Lymphoma (SLL)


 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.